thiazolidinedione


Also found in: Medical, Acronyms, Wikipedia.
Related to thiazolidinedione: Alpha-glucosidase inhibitor, DPP-4 inhibitor

thi·a·zol·i·dine·di·one

 (thī′ə-zō′lĭ-dēn′dĭ-ōn′)
n.
Any of a class of drugs that decrease insulin resistance and are used to treat type 2 diabetes.
References in periodicals archive ?
1 pounds were achieved when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks, added the company.
1 pounds were achieved when Bydureon BCise was used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks.
A subgroup of patients who were using thiazolidinedione alone or in combination with other antidiabetic drugs were analysed.
Pioglitazone is one of the thiazolidinedione and it reduces insulin resistance by acting on peripheral tissues including liver, skeletal muscles and adipose tissues and increase uptake of glucose through activation of PPARg5.
Madam, Pioglitazone is an antidiabetic of the thiazolidinedione (TZD) class.
Garber said the results are "much cleaner" using combinations of metformin with agents such as a thiazolidinedione, a dipeptidyl peptidase-4 inhibitor, or a sodium/glucose cotransporter-2 inhibitor.
Thiazolidinedione and metformin are widely used for the Non-Alcoholic Liver Disease (NAFLD) caused due to insulin resistance.
We will determine if adipocyte stra6 is transcriptionally regulated by the Peroxisome Proliferator-Activated Receptor gamma, the target of anti-diabetic thiazolidinedione drugs, and by weight gain in mice, as is known for RBP4 and RetSat.
If metformin at a maximum tolerated dose does not achieve the HbA1c target after 3 months, add a second oral agent (a sulfonylurea [SU], thiazolidinedione [TZD], dipeptidyl peptidase 4 [DPP-4] inhibitor, or sodium-glucose cotransporter-2 [SGLT2] inhibitor), a glucagon-like peptide-1 (GLP-1) receptor agonist, or a basal insulin (table 2).
The thiazolidinedione agent rosiglitazone now can be prescribed without complying with a Risk Evaluation and Mitigation Strategy (REMS), according to the Food and Drug Administration.
Reasonable combinations of drugs include a sulfonylurea plus metformin, a sulfonylurea plus an -glucosidase inhibitor, a sulfonylurea plus a thiazolidinedione, metformin plus repaglinide, biguanide plus [alpha]-glucosidase inhibitor, and metformin plus a thiazolidinedione (Lin and Sun 2010).
Interestingly, thiazolidinedione, an insulin sensitiser protected women against cancer (32 percent lowered risk) than an insulin secretagogue known as sulphonylurea.